Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -648.32% is 39% below its 1-year average of -466.74%, around the middle of its 1-year range (-1595.98%–0.00%).
38.90% below its 12-month average of -466.74%.
Reported quarterly profit margin; no daily interpolation. Q3 FY2026 (2026-06-30): -597.40%.
NET PROFIT MARGIN
-648.32%
NET PROFIT MARGIN AVG TTM
-466.74%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-38.90%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 430 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Citius Oncology, Inc.
Market Cap
$81.22M
Net Profit Margin
-648.32%
TTM Avg
-466.74%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$83.96M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$84.00M
Net Profit Margin
-4560.82%
TTM Avg
-1001.79%
3Y Avg
-692.03%
5Y Avg
-1554.36%
Market Cap
$84.70M
Net Profit Margin
-269.42%
TTM Avg
-19.58%
3Y Avg
-904.79%
5Y Avg
-881.91%
Market Cap
$84.75M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$86.69M
Net Profit Margin
6.21%
TTM Avg
8.02%
3Y Avg
-5.41%
5Y Avg
-4.66%
Market Cap
$87.86M
Net Profit Margin
-7884.06%
TTM Avg
-7191.86%
3Y Avg
-8225.67%
5Y Avg
-7676.39%
Market Cap
$74.35M
Net Profit Margin
-210.75%
TTM Avg
-289.10%
3Y Avg
-513.23%
5Y Avg
-2388.54%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | $81.22M | -648.32% | -466.74% | 0.00% | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | 0.00% | 0.00% | 0.00% | 0.00% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -4560.82% | -1001.79% | -692.03% | -1554.36% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | -269.42% | -19.58% | -904.79% | -881.91% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 6.21% | 8.02% | -5.41% | -4.66% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -7884.06% | -7191.86% | -8225.67% | -7676.39% |
| Hyperfine, Inc. (HYPR)vs › | $74.35M | -210.75% | -289.10% | -513.23% | -2388.54% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 2.57% | -5.95% | -14.59% | -10.91% |
Operating Margin
0.0%
Net Profit Margin
-648.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -597.40% |
| 2026-03-31 | -1595.98% |
| 2025-12-31 | -140.31% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
